Well,as I`ve said many times,the application should`nt have been applied for unless Adxs has a suitor in it`s grasp for PSA. MERCK. No more free rides for Merck on PSA,especially on the next gen of Adxs`s science. HOT/ PSA must have a paying partner to take it through the trials,and Adxs certainly does`nt have the money to do so. Thereby a partnership with Merck looks very likely. If so,once announced Adxs`s share price could start a major run up. Something like we saw in the year following the Amgn partnership,which took Adxs`s share price to 30.00 a share. Shareholders,and Adxs are way over due for something great and definitive,like a major upfront cash deal with Merck on HOT/PSA.